The U.S. Department of Health and Human Services (HHS) said it will not pursue enforcement against licensed pharmacies and physicians that temporarily compound six experimental peptides, including BPC-157 and TB-500, despite FDA scientists’ concerns about limited evidence for safety and effectiveness. The policy follows a contested recommendation process from outside advisers earlier this year. The guidance effectively widens access pathways for certain peptide products while leaving the evidence base and regulatory scrutiny questions unresolved. For compounding stakeholders, it clarifies enforcement posture; for clinicians and patients, it raises the practical issue of how prescribing decisions may proceed amid ongoing scientific uncertainty. The announcement also keeps the U.S. peptide debate squarely in regulatory limbo, with differences emerging between HHS enforcement discretion and the FDA evidence concerns raised by career reviewers. —